|
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR). |
|
|
No Relationships to Disclose |
|
|
Honoraria - AMGEN; AMGEN; AMGEN; AMGEN; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; PRMA Consulting; PRMA Consulting; PRMA Consulting; PRMA Consulting; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Xbiotech; Xbiotech; Xbiotech; Xbiotech |
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Guardant Health; Guardant Health; Guardant Health; Guardant Health; HalioDX; HalioDX; HalioDX; HalioDX; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Mundipharma; Mundipharma; Mundipharma; Mundipharma; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; SERVIER; SERVIER; SERVIER; SERVIER; Tesaro; Tesaro; Tesaro; Tesaro |
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems |
|
|
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical |
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER |
|
|
Consulting or Advisory Role - HalioDx; HalioDx; HalioDx; HalioDx; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; OSE Immunotherapeutics; OSE Immunotherapeutics; OSE Immunotherapeutics; OSE Immunotherapeutics; Pfizer; Pfizer; Pfizer; Pfizer |
Travel, Accommodations, Expenses - MSD; MSD; MSD; MSD |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche; Roche; Roche; Roche; Saton; Saton; Saton; Saton |
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER |
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; roche; roche; roche; roche; SERVIER; SERVIER; SERVIER; SERVIER |
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER |
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche |
|
|
Expert Testimony - Roche; Roche; Roche; Roche |
Travel, Accommodations, Expenses - Hospira; Hospira; Hospira; Hospira |
|
|
Research Funding - Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst) |
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Celgene; Celgene; Celgene; Celgene; Merck Serono; Merck Serono; Merck Serono; Merck Serono |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BIOCARTIS; BIOCARTIS; BIOCARTIS; BIOCARTIS; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi |
Consulting or Advisory Role - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck |
Patents, Royalties, Other Intellectual Property - Inventor of mir31-3p licence to integragen; Inventor of mir31-3p licence to integragen; Inventor of mir31-3p licence to integragen; Inventor of mir31-3p licence to integragen |
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb |
|
|
Employment - HalioDx; HalioDx; HalioDx; HalioDx |
Stock and Other Ownership Interests - HalioDx; HalioDx; HalioDx; HalioDx |
Other Relationship - HalioDx; HalioDx; HalioDx; HalioDx |
|
|
Employment - HalioDx; HalioDx; HalioDx; HalioDx |
Stock and Other Ownership Interests - HalioDx; HalioDx; HalioDx; HalioDx |
|
|
Stock and Other Ownership Interests - HalioDx; HalioDx; HalioDx; HalioDx |
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Sanofi; Sanofi; Sanofi; Sanofi |
Consulting or Advisory Role - Actelion; Actelion; Actelion; Actelion; Amgen; Amgen; Amgen; Amgen; HalioDx; HalioDx; HalioDx; HalioDx; Illumina; Illumina; Illumina; Illumina; IO Biotech; IO Biotech; IO Biotech; IO Biotech; Northwest Biotherapeutics; Northwest Biotherapeutics; Northwest Biotherapeutics; Northwest Biotherapeutics |
Research Funding - HalioDx (Inst); HalioDx (Inst); HalioDx (Inst); HalioDx (Inst); ImageIQ (Inst); ImageIQ (Inst); ImageIQ (Inst); ImageIQ (Inst); IO Biotech (Inst); IO Biotech (Inst); IO Biotech (Inst); IO Biotech (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Perkin Elmer (Inst); Perkin Elmer (Inst); Perkin Elmer (Inst); Perkin Elmer (Inst) |
Patents, Royalties, Other Intellectual Property - INSERM (Inst); INSERM (Inst); INSERM (Inst); INSERM (Inst) |
|
|
Honoraria - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; HalioDx; HalioDx; HalioDx; HalioDx; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre |
Research Funding - Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology |